Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: A systematic review for low- and middle-income countries

PharmacoEconomics

Volumn 29, Issue 7, 2011, Pages 579-599

  Galrraga, Omar ^a,b   Wirtz, Veronika J ^b,f   Figueroa Lara, Alejandro ^b   Santa Ana Tellez, Yared ^b   Coulibaly, Ibrahima ^c   Viisainen, Kirsi ^c   Medina Lara, Antonieta ^d   Korenromp, Eline L ^c,e  

^a BROWN UNIVERSITY   (United States)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c TUBERCULOSIS AND MALARIA   (Switzerland)

^d BOCCONI UNIVERSITY   (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f University Medical Center Rotterdam ^*  (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ANTIRETROVIRAL TREATMENT; ANTIVIRAL THERAPY; DRUG COST; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SOCIOECONOMICS; SYSTEMATIC REVIEW; VERTICAL TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CHILD; DRUG COSTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY;

EID: 79959272542     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11586120-000000000-00000     Document Type: Review

References (63)

1. WHO/UNAIDS/UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report. Geneva: WHO, 2009
2. Beck EJ, Santas XM, Delay PR. Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries. Aids 2008 Jul; 22 (Suppl. 1): S75-85
3. The Global Fund to Fight AIDS, Tuberculosis and Malaria Third Replenishment 2011-2013. Improving value for money in Global Fund-supported programs. Geneva: The Global Fund to Fight AIDS, Tuberculosis and Malaria, 2010 Mar [online]. Available from URL: http://www.theglobalfund.org/documents/ replenishment/2010/ Improving%20Value%20for%20Money%20in%20Global%20Fund%20Supported%20Programs.pdf [Accessed 2010 Mar 28]
4. Joint United Nations Programme on HIV/AIDS (UNAIDS). What countries need: investments needed for 2010 targets. Geneva: UNAIDS, 2009 [online]. Available from URL: http://data.unaids.org/pub/Report/2009/jc1681-what- countries-need-en.pdf [Accessed 2010 Jun 15]
5. UNAIDS and The World Bank Global HIV/AIDS program. The global economic crisis and HIV prevention and treatment programmes: vulnerabilities and impact. Washington, DC: The World Bank, 2009
6. Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008, HR5501, 110th Cong
7. UK Department for International Development. Achieving universal access: the UK-s strategy for halting and reversing the spread of HIV in the developing world. Monitoring performance and evaluating impact. 2008 [online]. Available from URL: http://www.aidsportal.org/repos/achieving-universal-access.pdf [Accessed 2011 Feb 17]
8. The Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund 2010: innovation and impact. Geneva: The Global Fund to Fight AIDS, Tuberculosis and Malaria, 2010 Mar [online]. Available from URL: http://www.theglobalfund. org/documents/replenishment/2010/Global-Fund-2010-Innovation-and-Impact-en.pdf [Accessed 2010 Jul 10]
9. Izazola-Licea JA, Wiegelmann J, Aran C, et al. Financing the response to HIV in low-income and middle-income countries. J Acquir Immune Defic Syndr 2009 Dec; 52 Suppl. 2: S119-26
10. UNAIDS. Country factsheets. Geneva: UNAIDS, 2010 Dec [online]. Available from URL: http://www.unaids.org/en/ dataanalysis/tools/aidsinfo/ countryfactsheets/ [Accessed 2011 Feb 19]
11. UNAIDS. Report on the global AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2010 http://www.unaids.org/globalreport/Global- report.htm [Accessed 2011 Feb 17]
12. Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care: a global review. Pharmacoeconomics 2001 Jan; 19 (1): 13-39 (Pubitemid 32113370)
13. Bollinger L, Stover J. Financial resources required to achieve universal access to HIV prevention, treatment, care and support: methodology for care and treatment interventions. 2007 [online]. Available from URL: http://data.unaids. org/pub/Report/2007/20070925-annex-iii-treatment-care-methodology-en.pdf [Accessed 2010 Apr 26]
14. Ades AE, Ratcliffe J, Gibb DM, et al. Economic issues in the prevention of vertical transmission of HIV. Pharmacoeconomics 2000 Jul; 18 (1): 9-22 (Pubitemid 30468864)
15. Beck EJ, Harling G, Gerbase S, et al. The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008. Curr Opin HIV AIDS 2010 May; 5 (3): 215-24
16. PRISMA. Preferred Reporting Items for Systematic Reviews and Meta-Analyses [online]. Available from URL: http://www.prisma-statement.org/ statement.htm [Accessed 2009 Feb 17]
17. World Bank. World Bank list of economies (July 2009) [online]. Available from URL: http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS [Accessed 2009 Jul 17]
18. International Monetary Fund. International exchange rates. Washington, DC: IMF, 2009
19. Cleary S, Tshehlo R, Jouquet G, et al. Ensuring access to free HIV/AIDS care and treatment in Lesotho. Capetown and Maseru: University of Cape Town,Ministry of Health & Social Welfare, Kingdom of Lesotho, Doctors Without Borders/Médecins Sans Frontières, Scott Hospital Health Service Area, 2007
20. Lesotho Central Bank. Official exchange rates. 2009 [online]. Available from URL: http://www.centralbank.org.ls/ statistics/ 2006%20Annual%20Report%20Tables1(final).pdf [Accessed 2009 Dec 15]
21. US Bureau of Labor Statistics. Consumer price index: historical dataset. Washington, DC: Bureau of Labor Statistics, 2009
22. Vella V, Govender T, Dlamini S, et al. Evaluation of antiretroviral therapy against HIV/AIDS in KwaZulu-Natal, South Africa. 2008 Oct [online]. Available from URL: http://www.kznhealth.gov.za/italian/arv.pdf [Accessed 2009 Dec 12]
23. PEPFAR ART Costing Project Team. The costs of comprehensive HIV treatment in Ethiopia: report of a cost study of PEPFAR-supported HIV treatment programs in Ethiopia. Atlanta (GA): CDC and PEPFAR, 2009
24. Marques HH, Couttolenc BF, Latorre Mdo R, et al. Costs of care provided in a university hospital for children exposed to or infected with the HIV/AIDS. Cad Saude Publica 2007; 23 Suppl. 3: S402-13
25. Hounton SH, Akonde A, Zannou DM, et al. Costing universal access of highly active antiretroviral therapy in Benin. AIDS Care 2008 May; 20 (5): 582-7
26. Bikilla AD, Jerene D, Robberstad B, et al. Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia. Cost Eff Resour Alloc 2009; 7: 6
27. Kombe G, David G, Raj G, et al. Human and financial resource requirements for scaling up HIV/AIDS services in Ethiopia. Bethesda (MD): The Partners for Health Reformplus Project, Abt Associates, 2004
28. Koenig SP, Riviere C, Leger P, et al. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc 2008; 6: 3
29. Jaffar S, Amuron B, Foster S, et al. Rates of virological failure in patients treated in a home-based versus a facilitybased HIV-care model in Jinja, southeast Uganda: a clusterrandomised equivalence trial. Lancet 2009 Dec 19; 374 (9707): 2080-9
30. Gupta I, Trivedi M, Kandamuthan S.Recurrent costs of India-s free ART program. In: HaackerM, Claeson M, editors. HIV and AIDS in South Asia: an economic development risk. Washington, DC:World Bank, 2009: xxvi, 244
31. John KR, Rajagopalan N, Madhuri KV. Brief communication: economic comparison of opportunistic infection management with antiretroviral treatment in people living with HIV/AIDS presenting at an NGO clinic in Bangalore, India. MedGenMed 2006; 8 (4): 24
32. Loubiere S, el Filal KM, Sodqi M, et al. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience. Antivir Ther 2008; 13 (2): 241-51 (Pubitemid 351535375)
33. Kombe G,Galaty D, Nwagbara C. Scaling-up antiretroviral treatment in the public sector in Nigeria: a comprehensive analysis of resource requirements. Washington, DC: Partners for Health Reform plus, Abt Associates, 2004
34. PHR. Nigeria: rapid assessment of HIV/AIDS care in the public and private sectors. Bethesda (MD): The Partners for Health Reformplus (PHR) Project, DELIVER, POLICY Project, Abt Associates, 2004
35. Kitajima T, Kobayashi Y, Chaipah W, et al. Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand. AIDS 2003 Nov 7; 17 (16): 2375-81 (Pubitemid 38147024)
36. Acurcio Fde A, Puig-Junoy J, Bonolo Pde F, et al. Costeffectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil. Rev Esp Salud Publica 2006 Jan-Feb; 80 (1): 41-54 (Pubitemid 44383631)
37. Aracena-Genao B, Navarro JO, Lamadrid-Figueroa H, et al. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico. AIDS 2008 Jul; 22 Suppl. 1: S141-8
38. Bautista-Arredondo S, Dmytraczenko T, Kombe G, et al. Costing ofHIV/AIDS treatment inMexico. Bethesda (MD): Partners for Health Reformplus Project, Abt Associates Inc., 2003. Report No. 020
39. Bautista-Arredondo S, Dmytraczenko T, Kombe G, et al. Costing of scaling up HIV/AIDS treatment in Mexico. Salud Publica Mex 2008; 50 Suppl. 4: S437-44
40. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa: a primary data analysis. Cost Eff Resour Alloc 2006; 4: 20
41. Deghaye N, Pawinski RA, Desmond C. Financial and economic costs of scaling up the provision of HAART to HIVinfected health care workers in KwaZulu-Natal. S Afr Med J 2006 Feb; 96 (2): 140-3 (Pubitemid 43263233)
42. Harling G, Bekker LG, Wood R. Cost of a dedicated ART clinic. S Afr Med J 2007 Aug; 97 (8): 593-6 (Pubitemid 47412019)
43. Harling G, Wood R. The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr 2007 Jul 1; 45 (3): 348-54 (Pubitemid 47012384)
44. Kevany S, Meintjes G, Rebe K, et al. Clinical and financial burdens of secondary level care in a public sector antiretroviral roll-out setting (G. F. Jooste Hospital). S Afr Med J 2009 May; 99 (5): 320-5
45. Martinson N, Mohapi L, Bakos D, et al. Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr 2009 Mar 1; 50 (3): 327-30
46. Rosen S, Long L, Sanne I. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. TropMed Int Health 2008 Aug; 13 (8): 1005-15
47. United Nations. Purchasing power parities (PPP) conversion factor, local currency unit to international dollar. Millennium Development Goals indicators 2010 [online]. Available from URL: http://unstats.un.org/unsd/mdg/Metadata.aspx? IndicatorId=0&SeriesId=699 [Accessed 2010 Feb 17]
48. Dandona L, Kumar SG, Ramesh YK, et al. Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India. BMC Health Serv Res 2008; 8: 26
49. Desmond C, Franklin L, Steinberg M. The prevention of mother-to-child HIV transmission: costing the service in four sites in South Africa.Durban: Health Systems Trust, 2004
50. McMennamin T, Fellow A, Fritsche G. Cost and revenue analysis in six Rwandan health centers: 2005 cost and revenues. Boston (MA): Management Sciences for Health (MSH), 2007
51. Guinness L, Arthur G, Bhatt SM, et al. Costs of hospital care for HIV-positive and HIV-negative patients at Kenyatta National Hospital, Nairobi, Kenya. AIDS 2002 Apr 12; 16 (6): 901-8 (Pubitemid 34409014)
52. Calmy A, Klement E, Teck R, et al. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. AIDS 2004 Dec 3; 18 (18): 2353-60 (Pubitemid 40065902)
53. Ford N, Wilson D, Costa Chaves G, et al. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS 2007 Jul; 21 Suppl. 4: S21-9 (Pubitemid 47051746)
54. Over M, Marseille E, Sudhakar K, et al. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options. Sex Transm Dis 2006 Oct; 33 (10 Suppl.): S145-52 (Pubitemid 44454729)
55. WHO Global Price Reporting Mechanism (GPRM). Transaction prices for antiretroviral medicines and HIV diagnostics from 2008 to March 2010 [online]. Available from URL: http://www.who.int/hiv/pub/amds/GPRMsummary-report-may2010. pdf [Accessed 2010 Jul 28]
56. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised noninferiority trial. Lancet 2010 Jan 9; 375 (9709): 123-31
57. Medina-Lara A, Kigozi J, Amurwon J, et al. Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring anti-retroviral therapy in Uganda and Zimbabwe (DART Trial). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009 Jul 19-22; Cape Town
58. Alcorn K. DART study shows HIV treatment without lab monitoring safe, effective in Africa. London: NAM Publications, 2009 Jul 21 [online]. Available from URL: http:// www.aidsmap.com/page/1435211/ [Accessed 2011 Mar 15]
59. Majchrowicz M. Beyond antiretroviral access: low-cost laboratory tests needed for the developing world. AIDS 2003; 17 Suppl. 4: S13-5
60. Schneider H, Blaauw D, Gilson L, et al. Health systems and access to antiretroviral drugs for HIV in Southern Africa: service delivery and human resources challenges. Reprod Health Matters 2006 May; 14 (27): 12-23 (Pubitemid 43732446)
61. Hirschhorn LR, Oguda L, Fullem A, et al. Estimating health workforce needs for antiretroviral therapy in resourcelimited settings. Hum Resour Health 2006; 4: 1
62. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 version. Geneva: WHO, 2010 [online]. Available from URL: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf [Accessed 2011 Feb 19]
63. Consorcio de Investigació n sobre VH/SIDA/TB [online]. Available from URL: http://www.cisidat.org.mx [Accessed 2011 Feb 17 ]